Tag: Artificial Intelligence

Lantern Pharma has signed a research collaboration with Bielefeld University for the development of novel antibody-drug conjugates (ADCs) with high therapeutic and anti-tumor potential. The partners will be using Lantern's proprietary Response Algorithm for Drug Positioning and Rescue (RADR®) artificial intelligence (AI) and machine learning (ML) platform , to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates.

OSE Immunotherapeutics,  a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases and deep...